Donald Bergstrom Sells 2,686 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,686 shares of the stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total transaction of $22,696.70. Following the sale, the insider owned 420,047 shares of the company’s stock, valued at $3,549,397.15. This trade represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Relay Therapeutics Stock Down 0.6%

Shares of RLAY stock opened at $7.66 on Friday. Relay Therapeutics, Inc. has a 52-week low of $1.77 and a 52-week high of $9.04. The stock’s 50-day moving average price is $7.97 and its 200 day moving average price is $5.97. The stock has a market capitalization of $1.33 billion, a PE ratio of -4.38 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.04). Analysts expect that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Analyst Upgrades and Downgrades

RLAY has been the topic of several analyst reports. Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $6.00 to $13.00 in a report on Friday, December 12th. Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.57.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Torren Management LLC acquired a new stake in shares of Relay Therapeutics in the 4th quarter worth approximately $30,000. Pictet Asset Management Holding SA acquired a new stake in Relay Therapeutics in the 4th quarter valued at about $127,000. UBS Group AG increased its stake in shares of Relay Therapeutics by 94.4% during the 4th quarter. UBS Group AG now owns 296,017 shares of the company’s stock worth $2,504,000 after purchasing an additional 143,764 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in Relay Therapeutics in the 4th quarter valued at approximately $1,203,000. Finally, Vanguard Group Inc. grew its holdings in Relay Therapeutics by 3.1% during the 4th quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock valued at $81,990,000 after buying an additional 295,701 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.